지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학위논문
- 저자정보
- 지도교수
- 임권택
- 발행연도
- 2015
- 저작권
- 부경대학교 논문은 저작권에 의해 보호받습니다.
이용수2
이 논문의 연구 히스토리 (3)
2020
- 이 논문의 후속연구가 궁금하신가요?
- 연관 학술논문 또는 학술발표를 통해 보다 발전된 연구결과를 확인하실 수 있습니다.
- 이 논문의 연구 히스토리 확인하기
초록· 키워드
오류제보하기
초임계 이산화탄소를 이용한 공정으로 퍼아세틸레이티드 사이클로덱스트린(peracetylated cyclodextrin (PAc CD))의 노즐 분사를 통하여 초미립자 크기 입자를 제조하였다. 초임계 유체에 용해된 물질을 급속 팽창함으로서 미립자를 만드는 통상적인 방법중인 RESOLV 방법은 가압된 초임계 용액을 계면활성제가 포함된 외부용액, 주로 물속으로 급속 팽창하는 방식이다. 고압 반응기 내부에 PAc-β-CD를 넣고 고압 실린지 펌프를 이용하여 가압한 후 45℃를 유지하며 교반기를 이용하여 교반시킨다. 얻어진 유체의 PAc-β-CD를 일정시간 뒤 50~150㎛ 구경의 모세관을 통하여 계면활성제가 포함된 수용액상으로 빠르게 방출하여 초미세 입자를 제조하였다. 초미세 입자의 크기를 SEM과 DLS를 사용하여 관찰한 결과 0.7~3.0㎛로 측정 되었다. 계면활성제의 변화, 압력의 변화, 모세관의 길이와 직경에 따른 다양한 실험조건에 대해서 입자 제조 결과를 조사하였고 omeprazole을 including시켜 drug delivery의 가능성을 확인 하였다.
목차
목차 ······························································································· ⅰList of Figures ·············································································· ⅲList of Tables ··············································································· ⅳAbstract ························································································ ⅴⅠ. 서 론 ························································································ 1Ⅱ. 이론적 배경 ··············································································· 62.1 초임계 유체 ··········································································· 62.2 초임계 이산화탄소 ·································································· 62.3 초임계 결정화 ········································································ 92.3.1 RESS ················································································ 92.3.2 GAS ················································································· 112.3.3 PGSS ················································································ 112.3.4 RPSS ················································································ 122.4 RESOLV ················································································ 122.5 PAc-β-CD(peracylated-β-cyclodextrin)··································· 132.6 OMP(Omeprazole)··································································· 132.7 Drug Delivery········································································ 14Ⅲ. 실 험 ························································································ 153.1 시 약 ···················································································· 153.2 실험장치 ················································································ 153.3 실험방법 ················································································ 173.4 분석방법 ················································································ 17Ⅳ. 결 과 ························································································ 184.1 PAc-β-CD의 결정···································································· 184.2 모세관의 변화 ········································································ 234.2.1 모세관의 길이 ·································································· 234.2.2 모세관의 직경 ·································································· 264.3 압력의 변화 ··········································································· 294.4 계면활성제의 변화 ·································································· 314.5 Drug(omeprazole)··································································· 34Ⅴ. 결 론 ························································································ 36Ⅵ. 참고문헌 ·················································································· 37
최근 본 자료
댓글(0)
0